Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001532943 XXXXXXXX LIVE 1 Common Stock, par value $0.001 per share 09/04/2026 false 0001636422 42225T107 Health Catalyst, Inc. 10897 South River Front Parkway #300 South Jordan UT 84095 Ryan L. Vardeman (214) 871-2700 8333 Douglas Ave Suite 775 Dallas TX 75225 Kellie Bobo (512) 867-8411 98 San Jacinto Blvd Suite 1500 Austin TX 78701 0001532943 N Palogic Value Management, LP b OO N DE 0.00 5366087.00 0.00 5374949.00 5374949.00 N 7.1 IA HC PN (1) The figures in: (a) Items 8, 10, and 11 include 5,366,087 shares of Common Stock of the Issuer held by Palogic Value Fund, LP, and (b) Items 10 and 11 also include 8,862 shares of Common Stock of the Issuer held by certain separately managed accounts (collectively, the "Managed Accounts"). (2) The figure in Item 13 is based upon 75,256,381 shares of Common Stock of the Issuer, par value $0.001 per share ("Common Stock") of Health Catalyst, Inc. (the "Issuer") outstanding as of July 31, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2026, filed by the Issuer with the U.S. Securities and Exchange Commission (the "SEC") on August 6, 2026. 0001387846 N Palogic Value Fund, LP b WC N DE 0.00 5366087.00 0.00 5366087.00 5366087.00 N 7.1 PN The figure in Item 13 is based upon 75,256,381 shares of Common Stock of the Issuer outstanding as of July 31, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2026, filed by the Issuer with the SEC on August 6, 2026. 0001494018 N Palogic Capital Management, LLC b OO N DE 0.00 5366087.00 0.00 5374949.00 5374949.00 N 7.1 HC OO (1) The figures in: (a) Items 8, 10, and 11 include 5,366,087 shares of Common Stock of the Issuer held by Palogic Value Fund, LP, and (b) Items 10 and 11 include 8,862 shares of Common Stock of the Issuer held by the Managed Accounts. (2) The figure in Item 13 is based upon 75,256,381 shares of Common Stock of the Issuer outstanding as of July 31, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2026, filed by the Issuer with the SEC on August 6, 2026. 0001574629 N Ryan L. Vardeman b PF OO N X1 6106.00 5366087.00 0.00 5374949.00 5374949.00 N 7.1 IN HC (1) The figure in Item 7 includes 6,106 shares of Common Stock of the Issuer held in an IRA of Mr. Vardeman, which account is managed by Palogic Value Management, but for which Palogic Value Management does not exercise voting authority. (2) The figures in: (a) Items 8, 10, and 11 include 5,366,087 shares of Common Stock of the Issuer held by Palogic Value Fund, LP, and (b) Items 10 and 11 include 8,862 shares of Common Stock of the Issuer held by the Managed Accounts. (3) The figure in Item 13 is based upon 75,256,381 shares of Common Stock of the Issuer outstanding as of July 31, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2026, filed by the Issuer with the SEC on August 6, 2026. Common Stock, par value $0.001 per share Health Catalyst, Inc. 10897 South River Front Parkway #300 South Jordan UT 84095 Item 3 is hereby amended and restated in its entirety as follows: "The Reporting Persons expended an aggregate of approximately $11,790,874 (including commissions) to acquire 5,374,949 shares of Common Stock of the Issuer in various open market transactions. The funds used to acquire the shares of Common Stock of the Issuer held by Palogic Value Fund were derived from the general working capital of Palogic Value Fund. The funds used to acquire the shares of Common Stock of the Issuer held by the Managed Accounts were derived from the general working capital or personal funds of the Managed Accounts or their ultimate owners." Item 4 is hereby amended and supplemented as follows: "On September 4, 2026, Palogic Value Management sent a letter (the "September 2026 Letter") to the Board of Directors of the Issuer following the Issuer's VitalWare sale. In the September 2026 Letter, Palogic Value Management applauded the sale and requested that the Board of Directors of the Issuer provide investors a clear, forward-looking business plan. Palogic Value Management further requested that the plan include specific and separated research and development costs, that the Issuer enhance disclosure regarding its revenue and related business metrics, and posed questions to the Board of Directors of the Issuer concerning its capital allocation framework and path to profitable growth. The foregoing description of the September 2026 Letter does not purport to be complete and is qualified in its entirety by the full text of the September 2026 Letter, which is attached hereto as Exhibit 99.4 and incorporated herein by reference." Item 5(a) is hereby amended and restated in its entirety as follows: "The aggregate number and percentage of the class of securities identified pursuant to Item 1 beneficially owned by each Reporting Person is stated in Items 11 and 13 on the cover page(s) hereto." Item 5(b) is hereby amended and restated in its entirety as follows: "(b) Number of shares as to which each Reporting Person has: (i) sole power to vote or to direct the vote: See Item 7 on the cover page(s) hereto. (ii) shared power to vote or to direct the vote: See Item 8 on the cover page(s) hereto. (iii) sole power to dispose or to direct the disposition of: See Item 9 on the cover page(s) hereto. (iv) shared power to dispose or to direct the disposition of: See Item 10 on the cover page(s) hereto." Item 5(c) is hereby amended and restated in its entirety as follows: "Other than as set forth on Annex A hereto, which is incorporated herein by reference, there have been no transactions in the class of securities reported on that were effected by the Reporting Persons during the past sixty days or since the most recent filing of Schedule 13D, whichever is less." Item 6 is hereby amended and restated in its entirety as follows: "The information set forth in Item 4 of this Schedule 13D is incorporated herein by reference. Except as otherwise described herein, no Reporting Person has any contract, arrangement, understanding or relationship with any person with respect to the Common Stock of the Issuer or any other securities of the Issuer." Item 6 is hereby amended and restated in its entirety as follows: "Exhibit 99.1 A Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Schedule 13D filed on June 22, 2026, by the Reporting Persons with the SEC). Exhibit 99.2 Annex A - Recent Transactions by the Reporting Persons in the Securities of the Issuer (filed herewith). Exhibit 99.3 Letter to the Issuer (incorporated by reference to Exhibit 99.3 to the Schedule 13D filed on June 22, 2026, by the Reporting Persons with the SEC). Exhibit 99.4 September 2026 Letter to the Issuer (filed herewith)." Palogic Value Management, LP Palogic Capital Management, LLC General Partner 09/08/2026 /s/ Ryan L. Vardeman Sole Member of the General Partner 09/08/2026 Palogic Value Fund, LP Palogic Value Management, LP General Partner 09/08/2026 Palogic Capital Management, LLC General Partner of the General Partner 09/08/2026 /s/ Ryan L. Vardeman Sole Member of the General Partner of the General Partner 09/08/2026 Palogic Capital Management, LLC /s/ Ryan L. Vardeman Sole Member 09/08/2026 Ryan L. Vardeman /s/ Ryan L. Vardeman Ryan L. Vardeman 09/08/2026